BridgeBio Pharma Inc
Q1 2026 Earnings
Market Reaction
S&P 500 over the same 30 days: −1.65%.
Did BBIO Beat Earnings? Q1 2026 Results
BridgeBio Pharma delivered a mixed first quarter for fiscal 2026, posting revenue of $194.51 million that cleared the $178.61 million consensus by 8.90% and surged 66.8% year over year, yet absorbing a deeper-than-expected loss as heavy commercial investment weighed on the bottom line. The company reported a loss per share of $0.84, falling short of the $0.62 consensus estimate by 36.21%, as selling, general, and administrative expenses climbed $57.50 million to support the ongoing Attruby buildout and pre-commercial preparation for three pipeline programs nearing launch. The revenue story was almost entirely Attruby-driven, with U.S. net product revenue for the ATTR-CM therapy reaching $180.60 million, up from $36.74 million a year ago, reflecting rapid prescribing growth and strong patient persistence. Looking ahead, BridgeBio expects to file three additional NDAs in 2026 for BBP-418, encaleret, and oral infigratinib, with all three potentially eligible for priority review, a pipeline breadth that has drawn notable institutional and high-profile investor interest in the stock.
- Strong prescribing growth and patient persistence driving Attruby commercial momentum
- Broad uptake among all patient types and HCP segments with particularly strong demand in treatment-naïve patients
- Royalty revenue growth from BEYONTTRA net product sales in EU and Japan
- Q1 2025 license and services revenue included $75 million milestone payment not recurring in Q1 2026
“I'm excited for the opportunity to begin educating on the differentiation we are seeing in the real world with Attruby, which is consistent with its biochemical differentiation. Furthermore, the company is in a period of focused execution, and I anticipate efficient filing, approval, and pre-commercial activities over the coming 12 months setting us up for three critical launches. Finally, because the company is fully financed but trading at a deep discount to intrinsic value, we think it prudent to begin share buybacks which at this point offer an attractive risk-adjusted return relative to other uses of capital.”
BridgeBio Pharma CEO, on the earnings call
Forward Guidance & Outlook
BridgeBio expects continued Attruby commercial momentum with broad uptake across patient types and HCP segments. The company plans three NDA submissions in 2026: BBP-418 for LGMD2I/R9 (already submitted, U.S. launch anticipated late 2026/early 2027), encaleret for ADH1 (NDA expected 1H 2026, U.S. launch early 2027), and infigratinib for achondroplasia (NDA expected Q3 2026, U.S. launch early to mid 2027). All three programs may be eligible for priority review. The company also plans to initiate RECLAIM-HP, a Phase 3 study of encaleret in chronic hypoparathyroidism, in summer 2026. Management views the stock as trading at a deep discount to intrinsic value and has authorized a $500 million share buyback program.
BBIO YoY Financials
BBIO Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.